APA (7th ed.) Citation

Bartolomeo, N., Kalyvianakis, K. K., Schuetz, Y. P., Nascimbeni, A. C., Castro, D. G., Crozat, B., . . . Ambresin, A. (2026). Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification. Ophthalmology & Therapy, 15(2), 831. https://doi.org/10.1007/s40123-026-01320-5

Chicago Style (17th ed.) Citation

Bartolomeo, Nicolò, Konstantinos Kitsos Kalyvianakis, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat, Mamadou Pathé Barry, and Aude Ambresin. "Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification." Ophthalmology & Therapy 15, no. 2 (2026): 831. https://doi.org/10.1007/s40123-026-01320-5.

MLA (9th ed.) Citation

Bartolomeo, Nicolò, et al. "Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification." Ophthalmology & Therapy, vol. 15, no. 2, 2026, p. 831, https://doi.org/10.1007/s40123-026-01320-5.